# Santa Ana Bio

> Santa Ana Bio is an Alameda, California, clinical-stage biotechnology company developing precision biologics for autoimmune and inflammatory diseases. Its lead investigational antibody, SAB01, binds both KIT and Siglec-6 to target mast cells; first participants were dosed in a Phase 1 healthy-volunteer study in September 2026. The privately held company disclosed $168 million in Series A and B financing at its 2024 launch and is developing additional antibody and antibody-drug-conjugate programs.

- **Founded:** 2022
- **Headquarters:** Alameda, United States
- **Founders:** Peter Emtage (Founder and CEO), Alexander Rudensky (Scientific founder), Richard Flavell (Scientific founder), Graham Lord (Scientific founder), Ansuman Satpathy (Scientific founder)
- **Products:** SAB01, SAB05, SAB06, Precision multi-omics platform
- **Notable:** Disclosed $168 million in combined Series A and B financing at its 2024 public launch., Advanced SAB01 into a first-in-human Phase 1 study, with first participants dosed in September 2026., Built a public pipeline spanning a bispecific mast-cell antibody, a CD40-targeted glucocorticoid conjugate, and multispecific gastrointestinal programs.

## Products & services

- **SAB01** — Investigational bispecific antibody engaging KIT and Siglec-6 to selectively deplete mast cells; in Phase 1 healthy-volunteer testing for safety, pharmacokinetics and pharmacodynamics.
- **SAB05** — Investigational CD40-targeted glucocorticoid antibody-drug conjugate designed to combine CD40 blockade with targeted steroid delivery; in IND-enabling development.
- **SAB06** — Portfolio of mono-, bi- and tri-specific antibodies designed around inflammatory bowel disease and other gastrointestinal pathways, including TL1A and IL-23; preclinical.
- **Precision multi-omics platform** — Internal discovery approach combining genomic, transcriptomic and proteomic data to identify disease-relevant cells and pathways.

## Achievements

- Disclosed $168 million in combined Series A and B financing at its 2024 public launch.
- Advanced SAB01 into a first-in-human Phase 1 study, with first participants dosed in September 2026.
- Built a public pipeline spanning a bispecific mast-cell antibody, a CD40-targeted glucocorticoid conjugate, and multispecific gastrointestinal programs.

## Latest updates

- **2026-09** — Announced first participants dosed in SAB01 Phase 1 healthy-volunteer study.
- **2026-02** — Appointed Newman Yeilding chief medical officer.
- **2025-11** — Appointed Mike Bonney chair of the board.

## Links

- Website: https://www.santaana.bio/
- LinkedIn: https://www.linkedin.com/company/santaanabio/

---

Profile page: https://yespress.io/santa-ana-bio
Published by YesPress — https://yespress.io
Last updated: 2026-09-30